168 related articles for article (PubMed ID: 32462910)
1. How biomarkers can improve pneumonia diagnosis and prognosis: procalcitonin and mid-regional-pro-adrenomedullin.
Spoto S; Legramante JM; Minieri M; Fogolari M; Terrinoni A; Valeriani E; Sebastiano C; Bernardini S; Ciccozzi M; Angeletti PS
Biomark Med; 2020 May; 14(7):549-562. PubMed ID: 32462910
[No Abstract] [Full Text] [Related]
2. Diagnostic and prognostic value of procalcitonin and mid-regional pro-adrenomedullin in septic paediatric patients.
Solé-Ribalta A; Bobillo-Pérez S; Valls A; Girona-Alarcón M; Launes C; Cambra FJ; Jordan I; Esteban E
Eur J Pediatr; 2020 Jul; 179(7):1089-1096. PubMed ID: 31974673
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.
Angeletti S; Spoto S; Fogolari M; Cortigiani M; Fioravanti M; De Florio L; Curcio B; Cavalieri D; Costantino S; Dicuonzo G
APMIS; 2015 Sep; 123(9):740-8. PubMed ID: 26058482
[TBL] [Abstract][Full Text] [Related]
4. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
5. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.
Travaglino F; De Berardinis B; Magrini L; Bongiovanni C; Candelli M; Silveri NG; Legramante J; Galante A; Salerno G; Cardelli P; Di Somma S
BMC Infect Dis; 2012 Aug; 12():184. PubMed ID: 22874067
[TBL] [Abstract][Full Text] [Related]
6. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
7. Procalcitonin and MR-Proadrenomedullin Combination with SOFA and qSOFA Scores for Sepsis Diagnosis and Prognosis: A Diagnostic Algorithm.
Spoto S; Cella E; de Cesaris M; Locorriere L; Mazzaroppi S; Nobile E; Lanotte AM; Pedicino L; Fogolari M; Costantino S; Dicuonzo G; Ciccozzi M; Angeletti S
Shock; 2018 Jul; 50(1):44-52. PubMed ID: 29023361
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
Liu D; Xie L; Zhao H; Liu X; Cao J
BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
[TBL] [Abstract][Full Text] [Related]
9. Procalcitonin and MR-proAdrenomedullin combination in the etiological diagnosis and prognosis of sepsis and septic shock.
Spoto S; Fogolari M; De Florio L; Minieri M; Vicino G; Legramante J; Lia MS; Terrinoni A; Caputo D; Costantino S; Bernardini S; Ciccozzi M; Angeletti S
Microb Pathog; 2019 Dec; 137():103763. PubMed ID: 31574301
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
[TBL] [Abstract][Full Text] [Related]
11. Mid regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study.
Viaggi B; Poole D; Tujjar O; Marchiani S; Ognibene A; Finazzi S
PLoS One; 2018; 13(8):e0201491. PubMed ID: 30102716
[TBL] [Abstract][Full Text] [Related]
12. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.
Heining L; Giesa C; Ewig S
Lung; 2016 Apr; 194(2):185-91. PubMed ID: 26748496
[TBL] [Abstract][Full Text] [Related]
13. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
[TBL] [Abstract][Full Text] [Related]
16. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
[TBL] [Abstract][Full Text] [Related]
18. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
[TBL] [Abstract][Full Text] [Related]
20. MR- proADM to detect specific types of organ failure in infection.
Andrés C; Andaluz-Ojeda D; Cicuendez R; Nogales L; Martín S; Martin-Fernandez M; Almansa R; Calvo D; Esteban-Velasco MC; Vaquero-Roncero LM; Ríos-Llorente A; Sanchez-Barrado E; Muñoz-Bellvís L; Aldecoa C; Bermejo-Martin JF
Eur J Clin Invest; 2020 Jun; 50(6):e13246. PubMed ID: 32307701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
